STRIPE partners in precision medicine series: provider perspective

Christine M. Formea,Paldeep Atwal,Kathryn Meintsma,Martin Dawes,Gary Marchant,Ben L. Kong,J. Shawn Jones,Sara L. Rogers

DOI: https://doi.org/10.1038/s41397-024-00348-9

2024-08-25

The Pharmacogenomics Journal

Abstract:During the "Provider Perspective" session, Dr. Paldeep Atwal, Kathryn Meintsma, Dr. Martin Dawes, and Dr. Gary Marchant provided their perspectives for health care providers who are considering the incorporation of science and technology into their clinical setting during a discussion moderated by Dr. Christine Formea. Speakers discussed areas of ongoing debate including genomics malpractice, clinical use, clinical decision support, and compliance. Dr. Paldeep Atwal MD, MBA, Physician and Director of Atwal Clinic for Genomic and Personalized Medicine and Medical Director for Genetic Services at Everly Health Solutions, shared a concierge clinic perspective. He discussed direct-to-consumer testing versus consumer-initiated testing approaches for pharmacogenomics. Direct-to-consumer testing does not require the involvement of a health care provider while consumer-initiated testing requires an order from a health care provider and is handled by the clinical care team. Consumer-initiated testing can be more beneficial for clinical decision making due to clinical oversight and CLIA-certified clinical laboratory testing. Pharmacogenomics barriers exist due to lack of awareness of its benefits. When patients initiate their own pharmacogenomics testing, barriers can be reduced to increase access. Additionally, Dr. Atwal recommended that health care providers seek the specialized expertise of pharmacogenomics-trained pharmacists as they begin incorporating these skills into their clinical practice. As non-genetics trained health care providers begin using this information, it is important to remember to use pharmacogenomics in conjunction with other medication information including drug-drug interactions and phenoconversion (i.e., a mismatch between a person's genotype-predicted drug metabolism and their actual or observed phenotypic drug metabolism due to non-genetic factors such as drug inducers or inhibitors) to create actionable medical plans that can be shared with patients and other health care providers for more effective clinical care. He encouraged using genomics resources such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) website for additional information.

pharmacology & pharmacy,genetics & heredity